Research has shown that fedratinib favorably impacts health-related quality of life for patients with myelofibrosis across the board, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Research has shown that fedratinib favorably impacts health-related quality of life for patients with myelofibrosis across the board, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Transcript
According to JAKARTA, how does fedratinib impact health-related quality of life for these patients? And does it impact patients differently based on fibrosis grade, spleen volume, or other factors?
Fedratinib is a JAK-2 inhibitor that is now approved for the therapy of patients with mild fibrosis. And what I presented at this meeting [61st American Society of Hematology Annual Meeting & Exposition] was a further analysis of our information both from the randomized study of the use of fedratinib and the upfront setting as well as in the second line setting.
So, what we observed is that fedratinib really can have a very significant favorable impact on health-related quality of life, both demonstrated by the improvement in symptoms, but also we had looked at other metrics of quality of life both the EQ [EuroQol]-5D in the JAKARTA study as well as the EORTC [European Organisation for Research and Treatment of Cancer] QLQ-C30, as well as a Patient Global Impression of Change in the JAKARTA-2 study. So, all of these, kind of, additional metrics show that in addition to improvement in symptoms, that really leads to a net improvement in the quality of life.
And we also looked at subset analysis to see was there a particular group that receives the benefit or, flipping it around, is there particular group that does not receive the benefit in terms of symptom improvement. Fortunately, we saw pretty much across the board, most patients have an improvement in their symptoms, regardless of fibrosis grade, regardless of their platelet count—whether that be 50 to 100 or above 100—regardless of baseline spleen size, or the presence of anemia. So, we're glad that there's that broad benefit, and then that it can help to improve health-related quality of life in myelofibrosis patients.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
2 Commerce Drive
Cranbury, NJ 08512